BTIG analyst Jeet Mukherjee raised the firm’s price target on Kymera Therapeutics (KYMR) to $75 from $59 and keeps a Buy rating on the shares. The stock has been the company’s top pick in the second half of 2025, having gone up 32% since July 1st, with the focus continuing to be on the phase 1b data in moderate to severe atopic dermatitis patients expected this quarter for KT-621, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Outperform at Mizuho
- Kymera Therapeutics price target raised to $80 from $60 at Citi
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan